喷油井
发表于 2025-3-25 07:14:13
http://reply.papertrans.cn/87/8683/868264/868264_21.png
Left-Atrium
发表于 2025-3-25 10:02:36
http://reply.papertrans.cn/87/8683/868264/868264_22.png
Myelin
发表于 2025-3-25 14:35:43
http://reply.papertrans.cn/87/8683/868264/868264_23.png
信徒
发表于 2025-3-25 18:38:43
http://reply.papertrans.cn/87/8683/868264/868264_24.png
Terrace
发表于 2025-3-25 21:10:29
Radiation Therapy for Non-melanoma Skin Cancer in Immunosuppressed Patients and Cutaneous Toxicity fngly linked with immunosuppressive treatment in organ transplant recipients (OTR). Population-based standard incidence ratios for SCC are increased 65–250-fold and for basal cell carcinomas 10–16-fold in OTR compared with non-transplanted population. Skin cancers in immunocompromised patients tend t
Esophagus
发表于 2025-3-26 01:27:00
Cutaneous Reactions to the Biologicsrelationship between biologics and inflammatory skin disease is complex and poorly understood, and clinical features may be atypical. It is important that clinicians understand how to recognise and manage these complications.
弄皱
发表于 2025-3-26 04:18:04
http://reply.papertrans.cn/87/8683/868264/868264_27.png
偏狂症
发表于 2025-3-26 12:10:03
Skin Cancer in the Immunocompromisednoids, surgical excision, as well as multidisciplinary care involving patient education and frequent dermatological examinations. In OTRs and autoimmune patients the revision of immunosuppression is also a key treatment consideration for aggressive skin cancers.
DOTE
发表于 2025-3-26 13:35:00
Book 2014atients and renal, heart, liver, bone marrow and lung transplant patients are surviving longer and are often experiencing skin side effects of immunity suppression. Diabetes is exploding in the USA and offers its own unique brand of immune suppressed skin diseases. Immunosuppressive drugs are being
amputation
发表于 2025-3-26 19:53:42
Skin Disorders in Patients with Primary Immunodeficiencies wide clinical, immunological, and genetic heterogeneity. Different mutations in the same gene may yield variable phenotypes. This chapter will detail the clinical manifestations, genetics and pathophysiology, diagnosis, and management of selected PIDs with a special focus on those with historically prominent cutaneous findings.